Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 1
2015 1
2018 3
2019 4
2020 7
2021 7
2022 10
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
An evolved AAV variant enables efficient genetic engineering of murine T cells.
Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, Chung JY, Xie WH, Allain V, Steinhart Z, Chang C, Talbot A, Kim S, Rosales A, Havlik LP, Pimentel H, Asokan A, Eyquem J. Nyberg WA, et al. Among authors: talbot a. Cell. 2023 Jan 19;186(2):446-460.e19. doi: 10.1016/j.cell.2022.12.022. Epub 2023 Jan 12. Cell. 2023. PMID: 36638795 Free PMC article.
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.
Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. Shy BR, et al. Among authors: talbot a. Nat Biotechnol. 2023 Apr;41(4):521-531. doi: 10.1038/s41587-022-01418-8. Epub 2022 Aug 25. Nat Biotechnol. 2023. PMID: 36008610 Free PMC article.
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies.
Goodman DB, Azimi CS, Kearns K, Talbot A, Garakani K, Garcia J, Patel N, Hwang B, Lee D, Park E, Vykunta VS, Shy BR, Ye CJ, Eyquem J, Marson A, Bluestone JA, Roybal KT. Goodman DB, et al. Among authors: talbot a. Sci Transl Med. 2022 Nov 9;14(670):eabm1463. doi: 10.1126/scitranslmed.abm1463. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350984 Free PMC article.
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.
Witkowski MT, Lee S, Wang E, Lee AK, Talbot A, Ma C, Tsopoulidis N, Brumbaugh J, Zhao Y, Roberts KG, Hogg SJ, Nomikou S, Ghebrechristos YE, Thandapani P, Mullighan CG, Hochedlinger K, Chen W, Abdel-Wahab O, Eyquem J, Aifantis I. Witkowski MT, et al. Among authors: talbot a. Nat Immunol. 2022 Oct;23(10):1424-1432. doi: 10.1038/s41590-022-01314-y. Epub 2022 Sep 22. Nat Immunol. 2022. PMID: 36138187 Free PMC article.
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP. Ferguson ID, et al. Among authors: talbot a. Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6. Nat Commun. 2022. PMID: 35840578 Free PMC article.
[Cryoglobulinemia for use].
Harel S, Talbot A. Harel S, et al. Among authors: talbot a. Rev Prat. 2018 Dec;68(10):1107-1112. Rev Prat. 2018. PMID: 30869220 French.
Pathological characteristics of light chain crystalline podocytopathy.
Nasr SH, Kudose S, Javaugue V, Harel S, Said SM, Pascal V, Stokes MB, Vrana JA, Dasari S, Theis JD, Osuchukwu GA, Sathick IJ, Das A, Kashkouli A, Suchin EJ, Liss Y, Suldan Z, Verine J, Arnulf B, Talbot A, Sethi S, Zaidan M, Goujon JM, Valeri AM, Mcphail ED, Sirac C, Leung N, Bridoux F, D'Agati VD. Nasr SH, et al. Among authors: talbot a. Kidney Int. 2023 Mar;103(3):616-626. doi: 10.1016/j.kint.2022.11.026. Epub 2022 Dec 26. Kidney Int. 2023. PMID: 36581019
Overcoming proteasome inhibitor resistance in the immunotherapy era.
Patiño-Escobar B, Talbot A, Wiita AP. Patiño-Escobar B, et al. Among authors: talbot a. Trends Pharmacol Sci. 2023 Aug;44(8):507-518. doi: 10.1016/j.tips.2023.05.006. Epub 2023 Jun 19. Trends Pharmacol Sci. 2023. PMID: 37344251 Free article. Review.
[Multiple myeloma treatment].
Talbot A, Royer B, Roussel M. Talbot A, et al. Rev Prat. 2018 Sep;68(7):787-791. Rev Prat. 2018. PMID: 30869334 French.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, Du Myélome IIF. Talbot A, et al. Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772. Haematologica. 2023. PMID: 37078253 Free PMC article.
41 results